Nonlinear Pharmacokinetics of Mibefradil in the Dog
Authors:
- 1 February 1996
- journal article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 85 (2) , 189-192
Abstract
The pharmacokinetics of mibefradil in the dog was evaluated in this study. Single intravenous (1 mg/kg) and three oral doses (1, 3, 6 mg/kg) of mibefradil were administered to three dogs according to a randomized complete block design, where dogs were blocks and treatments randomly assigned to each block. Systemic plasma clearance, volume of distribution at steady-state and half-life after intravenous administration were as follows: ClS = 18.4 +/- 1.2 mL/min/kg, VSS = 9.7 +/- 3.8 L/kg, and T1/2 = 9.5 +/- 3.4 h. Oral plasma clearance decreased with an increase in dose, from 101.8 +/- 18.8 mL/min/kg at 1 mg/kg to 21.7 +/- 4.3 mL/min/kg at a 6 mg/kg dose (p < 0.05). Half-life values did not change significantly with an increase in oral dose in all the animals studied (10.6 +/- 1.5 h at 1 mg/kg to vs 13.4 +/- 3.5 h at 6 mg/kg). Dose-normalized AUC ratios between the oral and intravenous treatments increased from 0.18 +/- 0.03 at 1 mg/kg to 0.87 +/- 0.21 at a 6 mg/kg dose (p < 0.05). The nonlinear kinetic behavior of mibefradil is consistent with an increase in gut absorption and/or reduction in elimination after higher oral doses. Although both dogs and humans exhibit nonlinear pharmacokinetics after oral administration, there are substantial differences in the clearance and volume of distribution values between these two species. Even though these differences can, in part, be accounted for by the difference in plasma protein binding, the use of the dog as an animal model for human mibefradil pharmacokinetics need to be qualified.Keywords
This publication has 11 references indexed in Scilit:
- High-performance liquid chromatographic analysis of mibefradil in dog plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Effects of the calcium channel blockers, diltiazem and Ro 40–5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing‐induced heart failureBritish Journal of Pharmacology, 1994
- Selective inhibition of T-type Ca2+ channels by Ro 40-5967.Circulation Research, 1994
- Cardiovascular Profile of Ro 40–5967, a New Nondihydropyridine Calcium Antagonist, Delineated in Isolated, Blood-Perfused Dog HeartsJournal of Cardiovascular Pharmacology, 1993
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillationEuropean Journal of Pharmacology, 1992
- Lack of Negative Inotropic Effects of the New Calcium Antagonist Ro 40–5967 in Patients with Stable Angina PectorisJournal of Cardiovascular Pharmacology, 1991
- A chronic conscious dog model for direct transhepatic studies in normal and pancreatic islet cell transplanted dogsJournal of Pharmacological Methods, 1991
- A computer simulation of the food effect: Transient changes in hepatic blood flow and michaelis‐menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranololBiopharmaceutics & Drug Disposition, 1990
- LAGRAN program for area and moments in pharmacokinetic analysisComputer Programs in Biomedicine, 1983